BiotechTube
WuXi Biologics

WuXi Biologics

WXXWY
Wuxi, China· Est. 2014

WuXi Biologics is a premier global CDMO that offers comprehensive biologics services spanning discovery, development, testing, and manufacturing of complex biologics including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. The company operates multiple GMP facilities across China, Ireland, Germany, Singapore, and the United States, with a total capacity exceeding 280,000 liters of bioreactors. With a client base of over 500 global partners and an integrated platform covering the entire biologics value chain, WuXi Biologics has enabled the advancement of numerous biologics programs from preclinical through commercial stages.

wuxibiologics.com

WXXWY · Stock Price

USD 8.91+2.16 (+32.00%)
Market Cap: $17.0B

Historical price data

AI Company Overview

WuXi Biologics is a premier global CDMO that offers comprehensive biologics services spanning discovery, development, testing, and manufacturing of complex biologics including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. The company operates multiple GMP facilities across China, Ireland, Germany, Singapore, and the United States, with a total capacity exceeding 280,000 liters of bioreactors. With a client base of over 500 global partners and an integrated platform covering the entire biologics value chain, WuXi Biologics has enabled the advancement of numerous biologics programs from preclinical through commercial stages.

OncologyImmunologyOphthalmologyMetabolic DiseasesInfectious DiseasesCell and Gene Therapy

Technology Platform

Integrated biologics CDMO platform providing end-to-end services from discovery through commercial manufacturing, including proprietary WuXiBody™ antibody discovery platform and advanced cell line development capabilities.

Pipeline

1
1 drug in pipeline1 in Phase 3
DrugIndicationStageWatch
Bevacizumab in Combination With Paclitaxel/Carboplatin + IBI...NSCLCPhase 3

Funding History

3
Total raised:$936M
PIPE$403MFeb 15, 2021
IPO$503MJun 13, 2017
Series A$30MJun 15, 2015

Opportunities

Significant growth opportunities exist through global capacity expansion, entry into cell and gene therapy manufacturing, and capturing increasing demand for biologics CDMO services as more companies outsource complex manufacturing.
Geographic diversification reduces geopolitical risks while expanding market access.

Risk Factors

Key risks include geopolitical tensions affecting international client relationships, intensifying competition from other CDMOs expanding capacity, potential regulatory changes in key markets, and operational risks associated with complex biologics manufacturing that could impact client relationships.

Competitive Landscape

Competes with major CDMOs including Lonza, Samsung Biologics, Catalent, and Fujifilm Diosynth, but differentiates through integrated end-to-end platform, competitive cost structure with high quality, and rapid global capacity expansion. Strong market position as one of the world's largest biologics CDMOs by capacity and client base.